Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Analyst, Ritu Baral, said, "Reiterate rating and price target on generic Copaxone, biosimilars potential, modest m-enox revenue stream. The stay on the enox injunction returned the m-enox revenue to a modest royalty stream to MNTA. We expect progress on biosimilars candidates from the Baxter (NYSE: BAX) deal in 2012/2013. We expect the generic Copaxone suit to resolve in MNTA’s favor mid-2012."

http://www.streetinsider.com/Analyst+Comments/Canaccord+Genuity+Reiterates+a+Buy+on+Momenta+Pharmaceuticals+(MNTA)%3B+Mgmt+Meeting+Takeaways%3A+FDA+Desire+to+Use+505(j)+for+M356/7172728.html